Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Pipobroman API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Pipobroman | CAS No: 54-91-1 | GMP-certified suppliers
A medication that treats polycythaemia vera and refractory chronic myeloid leukemia by providing cytoreductive therapy to manage abnormal blood cell proliferation.
Therapeutic categories
Primary indications
- For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia
Product Snapshot
- Pipobroman is available as an oral tablet formulation
- It is indicated for the treatment of polycythaemia vera and refractory chronic myeloid leukemia
- The product has received regulatory approval
Clinical Overview
Pharmacodynamically, pipobroman functions as an alkylating agent, structurally related to other DNA alkylators. Although its precise mechanism of action remains incompletely defined, it is believed to exert cytotoxic effects by alkylation of DNA, causing disruption of DNA synthesis and ultimately leading to cell death. This mechanism underpins its clinical activity against myeloproliferative disorders such as polycythaemia vera and essential thrombocythemia, where excessive proliferation of hematopoietic cells is pathogenic.
Key pharmacokinetic parameters for pipobroman have not been extensively characterized in the literature. As a cytotoxic alkylating agent, it is expected to require careful dosing and monitoring due to potential systemic toxicity. Safety considerations include myelosuppression, potential mutagenicity, and secondary malignancies, consistent with the class effects of alkylating anticancer drugs. Toxicity monitoring and risk assessment are integral components of its therapeutic use.
Pipobroman has been approved in several jurisdictions for its indicated uses but is not widely marketed internationally. It finds use primarily in hematologic oncology settings where alternative cytoreductive agents are ineffective or contraindicated.
From an API procurement perspective, manufacturers and sourcing specialists should ensure compliance with relevant pharmacopeial standards and regulatory requirements. Given the compound’s classified toxicity and potential hazards, handling protocols must meet stringent safety and quality audits. Supplier qualification should confirm consistent purity, absence of genotoxic impurities, and adherence to Good Manufacturing Practice (GMP) guidelines to support safe formulation development and clinical use.
Identification & chemistry
| Generic name | Pipobroman |
|---|---|
| Molecule type | Small molecule |
| CAS | 54-91-1 |
| UNII | 6Q99RDT97R |
| DrugBank ID | DB00236 |
Pharmacology
| Summary | Pipobroman is an antineoplastic agent that targets DNA through alkylation, disrupting DNA synthesis and inducing cell death. It is primarily indicated for the treatment of polycythemia vera and refractory chronic myeloid leukemia. Its pharmacodynamic activity is consistent with DNA-alkylating agents of similar structure. |
|---|---|
| Mechanism of action | The mechanism of action is uncertain, but due to the structural similarity with other DNA alkylating agents, pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death. |
| Pharmacodynamics | Pipobroman is an antineoplastic agent. Specifically, it is a piperazine derivative with a chemical structure close to that of many DNA alkylating agents. Pipobroman has well-documented clinical activity against polycythemia vera and essential thrombocythemia. |
Targets
| Target | Organism | Actions |
|---|---|---|
| DNA | Humans | cross-linking/alkylation |
ADME / PK
| Absorption | Well absorbed from the GI tract. |
|---|
Formulation & handling
- Pipobroman is a small molecule suitable for oral tablet formulations with moderate water solubility.
- The compound's piperazine ring structure suggests chemical stability under standard handling conditions without special protective measures.
- Due to its small molecule nature and low LogP, it is not expected to be sensitive to food intake during dosing.
Regulatory status
Supply Chain
| Supply chain summary | Pipobroman is manufactured by a single originator company, Abbott Laboratories Pharmaceutical Products Division. The branded product has a global presence, including markets in the US, EU, and other regions. Patent expiries suggest the potential for existing or forthcoming generic competition in the supply chain. |
|---|
Safety
| Toxicity | Symptoms of overdose include hematologic toxicity, especially with chronic overdosage. |
|---|
- Prolonged exposure may result in hematologic toxicity
- Monitor cumulative dosing carefully
- Handle with appropriate protective equipment to prevent accidental ingestion or inhalation
Pipobroman is a type of Cytostatic antibiotics
Cytostatic antibiotics are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various types of cancer. These antibiotics possess powerful cytostatic or cell-inhibiting properties, which impede the growth and division of cancer cells.
Cytostatic antibiotics work by selectively targeting and inhibiting specific enzymes and proteins necessary for the replication and proliferation of cancer cells. By interrupting these vital cellular processes, these APIs effectively hinder the progression of cancer and prevent the spread of malignant cells.
One prominent example of a cytostatic antibiotic is Doxorubicin, which belongs to the anthracycline class of antibiotics. Doxorubicin functions by intercalating with DNA molecules, preventing DNA replication and inhibiting the activity of topoisomerase enzymes. These mechanisms effectively impede the growth and division of cancer cells.
Another commonly used cytostatic antibiotic is Mitomycin C. It exerts its anticancer effects by inducing DNA cross-linking, leading to the inhibition of DNA synthesis and cell division. This antibiotic is particularly effective against a variety of solid tumors.
Cytostatic antibiotics are administered in different ways, such as intravenous injection or oral consumption, depending on the specific drug. These APIs are often used in combination with other chemotherapy agents or treatment modalities to achieve optimal therapeutic outcomes.
In conclusion, cytostatic antibiotics are a vital subcategory of pharmaceutical APIs used in cancer treatment. Their ability to inhibit cell growth and division makes them essential in combating various types of cancer, ultimately improving patient outcomes.
Pipobroman (Cytostatic antibiotics), classified under Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
Pipobroman API manufacturers & distributors
Compare qualified Pipobroman API suppliers worldwide. We currently have 1 companies offering Pipobroman API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Seratec | Producer | France | France | CoA, GMP | 5 products |
When sending a request, specify which Pipobroman API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Pipobroman API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
